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Abstract
Despite the widespread use of caffeine as a central ner-
vous stimulant, the central pharmacodynamic properties
of the drug have not yet been conclusively evaluated in
humans. The present study was undertaken to assess the
acute effects of caffeine on measures of topographical
quantitative electroencephalogram (EEG) in normal sub-
jects. Ten healthy male volunteers (mean age B SD 25 B
4 years) received placebo and 200 mg of caffeine as pow-
der with oral water solution (caffeine amount = 2 cups of
coffee) under randomized, double-blind crossover condi-
tions on two different occasions. Before administration
and 30 min afterwards, a 17-channel quantitative EEG
was recorded during relaxation with eyes open and
closed (15 min each). Caffeine caused a significant re-
duction of total EEG power at fronto-parieto-occipital and
central electrode positions of both hemispheres when
the subjects kept their eyes open. Absolute power of the
slow and fast alpha and slow beta activities was dimin-
ished in various regions of the brain (p ! 0.05). The effect
was more pronounced with the subjects keeping their
eyes open than with eyes closed. It can be concluded that
quantitative EEG is a sensitive method to assess the
effects of psychostimulants on the human brain. There-
fore, in pharmaco-EEG studies, environmental factors
such as caffeine have to be excluded.
Copyright © 2002 S. Karger AG, Basel
Introduction
Caffeine (1,3,7-trimethylxanthine), a component of
tea, coffee and soft drinks, is the most widely used psy-
choactive agent in the world [1]. Studies in North Ameri-
ca show a daily intake of approximately 200 mg per adult
[2]. The acute administration of this dose increases alert-
ness, stimulates attention and restores performance de-
graded by factors such as fatigue and boredom [3]. How-
ever, a wide variation in the behavioral effects of caffeine
has been demonstrated in humans receiving doses of this
magnitude [4]. The changes in brain state brought about
by caffeine are generally described in terms of increases in
excitatory processes, reduced inhibitory processes and/or
increased availability of energy. The global picture of
excitatory effects has correlates at the global-physiologic
level manifest in the spontaneous background electroen-
cephalogram (EEG). Topographical quantitative EEG
measures provide a neurophysiological assessment of
brain activity that correlates with behavior [5]. EEG pow-
er spectrum variables have been used for classification of
psychotropic drugs such as stimulants, antidepressants
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Table 1. Total EEG power (1.25–35.00 Hz)
Electrode EEG power with eyes open, Hz
baseline caffeine baseline placebo
EEG power with eyes closed, Hz
baseline caffeine baseline placebo
Fz 28.9 (43.8) 26.3 (38.6)* 26.6 (47.9) 30.8 (53.3) 33.5 (75.4) 29.5 (72.7) 36.2 (85.5) 42.7 (75.6)
F3 27.5 (54.6) 25.9 (51.4)* 24.4 (53.6) 27.8 (50.6) 30.8 (74.9) 27.5 (70.6) 34.9 (82.1) 38.6 (67.9)
F4 25.8 (78.1) 22.0 (32.3)* 24.5 (62.5) 27.1 (54.8) 33.1 (81.1) 29.3 (83.2) 35.4 (75.5) 41.7 (82.7)
F7 40.1 (57.8) 39.1 (79.5) 38.6 (87.6) 42.4 (90.0) 38.1 (69.9) 37.5 (65.9) 37.5 (66.2) 40.1 (63.9)
F8 36.3 (187.8) 33.4 (99.4) 37.2 (91.8) 38.2 (106.2) 38.0 (67.8) 40.4 (73.1) 40.0 (55.5) 42.5 (68.6)
Cz 14.7 (30.2) 12.5 (24.0)* 11.8 (36.3) 12.5 (28.6) 19.5 (64.0) 17.1 (50.1) 20.4 (45.5) 23.7 (50.1)
C3 16.9 (24.1) 12.9 (21.1)* 15.1 (26.5) 16.2 (24.8) 20.8 (45.4) 17.2 (45.6) 20.3 (46.8) 23.8 (42.1)
C4 16.7 (26.1) 13.0 (18.8)* 13.8 (20.9) 17.5 (21.9) 20.7 (34.6) 17.7 (37.6) 23.9 (29.9) 24.3 (33.8)
T3 22.7 (41.4) 20.0 (27.1) 22.2 (59.8) 23.5 (38.8) 22.0 (50.8) 21.0 (35.5) 25.2 (60.9) 25.7 (55.0)
T4 21.9 (31.4) 22.5 (38.2) 20.0 (34.0) 21.4 (33.5) 24.3 (55.3) 22.1 (52.9) 26.4 (41.7) 26.7 (54.4)
T5 20.8 (35.9) 17.1 (29.7) 23.7 (38.1) 22.3 (34.8) 40.2 (63.1) 30.4 (82.8) 40.3 (91.7) 49.2 (93.1)
T6 25.2 (51.8) 21.1 (41.3)* 21.5 (56.6) 21.7 (46.3) 48.0 (178.0) 57.9 (151.2) 53.5 (146.2) 54.3 (157.7)
Pz 22.0 (69.2) 18.1 (29.1) 20.8 (33.6) 21.6 (45.0) 35.8 (140.9) 29.2 (133.0) 31.5 (109.1) 34.9 (141.0)
P3 20.8 (31.3) 16.5 (25.9)* 23.3 (35.3) 20.6 (32.9) 36.4 (68.4) 24.1 (69.2) 32.9 (62.7) 41.9 (75.2)
P4 20.9 (65.7) 17.0 (26.0)* 18.9 (27.4) 20.8 (32.1) 37.8 (145.1) 36.7 (132.6) 34.4 (94.5) 35.6 (105.4)
O1 29.9 (28.1) 22.6 (30.7)* 30.4 (42.7) 32.4 (54.0) 55.6 (97.2) 74.0 (112.1) 74.6 (153.8) 58.1 (155.5)
O2 30.3 (36.9) 24.1 (35.9)* 34.4 (54.7) 32.6 (44.0) 70.3 (76.5) 64.7 (122.5) 88.0 (140.7) 83.8 (107.3)
Results are shown as median and range in parentheses. * p ! 0.05 versus baseline and placebo.
and tranquilizers [6]. However, previous studies on the
effect of caffeine on EEG are inconsistent regarding the
direction of the effect of caffeine on EEG power. Kene-
mans and Lorist [7] as well as Dimpfel et al. [8] found
reductions in power, whereas Hasenfratz and Bättig [9]
and Etevenon et al. [10] found increases. Difficulties in
comparing the power shifts across studies are due to the
circumstance that some experiments compare baseline
effects with a single dose while others compare changes
across a range of caffeine doses. The present study was
undertaken to rigorously examine the effects of 200 mg of
caffeine given as a single dose to healthy subjects on the




Ten healthy male subjects aged 22–33 years (mean B SD 25 B 4
years), weighing between 59 and 84 kg (71 B 8 kg) and 171–184 cm
(179 B 5 cm) in height were enrolled in the study. The study was
conducted according to the Declaration of Helsinki (Sommerset
West Amendment 1996). Written informed consent from the sub-
jects and approval from the Hospital Ethics Committee (Dresden,
Germany) were obtained. The subjects were moderate users of caf-
feine. This means they consumed 1–2 cups of coffee per day. They
were included after a standard physical examination, clinical labora-
tory tests and a 12-lead ECG.
Protocol
The subjects were not allowed to smoke or to consume alcoholic
or caffeine-containing beverages for 10 h before and during the trial.
They had to have been free of medication for at least 14 days. After
an overnight fast, the subjects presented themselves in the morning.
They received 200 mg of caffeine orally as powder with 150 ml of
water solution as well as placebo (glucose) on two different occasions
under randomized, double-blind, crossover conditions. All record-
ings took place in a quiet room with the subjects sitting in a comforta-
ble chair.
Quantitative EEG was recorded before and 30 min after inges-
tion of caffeine and placebo with the subjects keeping their eyes open
and closed for periods of 15 min each. Heart rate was monitored by
hand at the end of each period.
Topographical Quantitative EEG
Data acquisition and signal analysis followed the guidelines of the
International Pharmaco-EEG Group [11]. Details of the methods
have been described elsewhere [12]. Briefly, the EEG was recorded
bipolarly from 17 surface electrodes by means of an electrode cap
according to the standard 10–20 system with Cz as physical refer-
ence. EEG signals were amplified with a Cateem® apparatus (Pro-
science, Linden, Germany) and sampled at a rate of 512 Hz and 12
bit. ECG and electrooculogram were recorded simultaneously. Arti-
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facts were rejected automatically. Analog signals were displayed on a
separate monitor for visual control. The signals of all EEG electrodes
were frequency analyzed with the fast Fourier transformation, based
on sweeps of 4-second data epochs by means of a Hanning window.
In the resulting spectrum, six frequency bands were defined: delta
(1.25–4.50 Hz), theta (4.75–6.75 Hz), alpha1 (7.00–9.50 Hz), alpha2
(9.75–12.50 Hz), beta1 (12.75–18.50 Hz) and beta2 (18.75–35.00
Hz). Absolute power values (ÌV2) were calculated for the frequency
bands and the entire spectrum (1.25–35.00 Hz).
Statistical Analysis
All data were analyzed using the Sigma Stat software package
(Jandel, San Rafael, Calif., USA). Evaluation was done with a one-
way ANOVA procedure for repeated measurements. Friedman re-
peated-measures ANOVA on ranks was performed when values were
not normally distributed. If significant, Student-Newman-Keuls post
hoc tests were used for comparisons between treatment conditions.
Statistical significance was accepted at p ! 0.05.
Results
After administration of caffeine, total power in the
quantitatively analyzed EEG was significantly reduced at
frontal (Fz, F3, F4), central (Cz, C3, C4), temporal (T6),
parietal (P3, P4) and occipital (O1, O2) electrode positions
when the subjects kept their eyes open (p ! 0.05; table 1).
A trend in the same direction was seen with eyes closed in
frontal (Fz, F3, F4, F7), central (Cz, C3, C4), temporal (T3,
T4, T6), parietal (P3, P4, Pz) and occipital leads (O2),
although statistical significance was not reached (p 1
0.05). As shown in figures 1 and 2, caffeine significantly
reduced absolute power in the slow and fast alpha (alpha1
and alpha2) as well as the slow beta (beta1) frequency
ranges at various electrode positions under the eyes open
condition. Alpha power was not significantly affected,
whereas beta1 power was reduced when the subjects kept
their eyes closed. Theta and delta activities were dimin-
ished in a few leads under both conditions. No concomi-
tant changes in heart rate were noted. No specific topo-
graphical distribution of the EEG changes was noted.
However, the reduction of alpha power was accentuated
in frontal and occipital regions of both hemispheres
(fig. 1, 2).
Discussion
This study confirms the findings of a number of recent
studies that caffeine attenuates total power (1.5–35 Hz) in
the quantitatively analyzed EEG [7, 8, 13, 14]. The effect
was observed at frontal, parietal, occipital and central
electrode positions. All frequency ranges were concerned,
Fig. 1. Spectral power changes following oral
administration of 200 mg of caffeine. Filled
circles show a decrease (p ! 0.05) and open
circles no significant change (p 1 0.05) as
compared with baseline and placebo.
but the effect was most pronounced in the slow and fast
alpha bands with the subjects keeping their eyes open.
The lack of a specific topographical pattern of the EEG
changes may be due to the limited topographical resolu-
tion of pharmaco-EEG. The decrease in the alpha fre-
quency ranges is consistent with the notion that caffeine
increases cortical activation, excitability and/or arousal
[15]. Attenuation of alpha as well as total power has also
been reported with other psychostimulants such as am-
phetamine [13, 16]. Contrasting reports in the literature
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Fig. 2. Topographical representation of decreases in alpha1 frequencies following oral administration of 200 mg of
caffeine under the eyes open condition. Documentation of all values was made according to the ‘glow mode’ (50–
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of minimal or no effects [17, 18] or power-increasing
effects of caffeine [9, 10] seem to be due to differences in
baseline, dose and even recording conditions, e.g. resting
EEG versus vigilance-controlled EEG. Although not the
focus of the present study, other studies have shown that
withdrawal from caffeine results in an increase in EEG
power which can be reversed by administration of caf-
feine [19, 20].
The primary mechanism of action of caffeine is adeno-
sine receptor antagonism, by blocking cAMP formation
[21]. Since adenosine, a neuromodulator released during
normal cortical metabolic activity, acts to depress synap-
tic activity and inhibit neurotransmitter release, con-
sumption of caffeine acts as a powerful moderator of this
function. In addition, caffeine ingestion has also been
associated with increases in the rate of catecholamine syn-
thesis [15], which is significant with respect to the stimu-
lant properties of caffeine, because of the role that the re-
ticular system plays in the modulation of cortical arousal.
The stimulant effects of caffeine are associated with
changes in the local rates of cerebral energy metabolism.
Experiments in rats show that acute doses of caffeine
of 10 mg/kg increase cerebral glucose utilization in mono-
aminergic cell groupings like the substantia nigra and ven-
tral tegmental area, which are rich in dopamine, medial
and dorsal raphe nuclei, which contain serotonin, and the
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locus ceruleus, which is rich in noradrenaline [22]. Caf-
feine increases the rates of energy metabolism in the struc-
tures of the extrapyramidal motor system and in numer-
ous thalamic nuclei and limbic areas such as the hippo-
campus [23]. These local increases of cerebral glucose uti-
lization which are involved in the sleep/wake cycle corre-
late with behavioral modifications as mentioned above
[15]. Caffeine induces a decrease in local cerebral blood
flow, mainly in the areas where it increases metabolism,
i.e. in monoaminergic cell groupings, in the limbic system
and in the thalamus [24]. Contrary to the majority of
pharmacological agents to which humans are frequently
exposed, caffeine has the property of inducing cerebral
hypoperfusion accompanied by a simultaneous increase
in glucose utilization. Like other methylxanthines, e.g.
theophylline, caffeine thus seems to modify the regulating
mechanism between blood flow and cerebral metabolism
in the CNS. Although this mechanism is not yet well
understood, adenosine, with which methylxanthines com-
pete, is known to be one of the modulators of the regula-
tion of the relationship of blood flow to metabolism in the
central nervous system [25]. It is highly speculative to
extend conclusions from experiments in animals such as
rats to humans. Parameters of quantitative EEG can be
employed to monitor drug effects on cerebral blood flow
and metabolism in humans [26]. Vasodilating agents such
as glyceroltrinitrate increase EEG power, whereas vaso-
constricting agents such as indomethacin decrease EEG
power in healthy subjects [27, 28]. In the present study,
200 mg of caffeine, which is comparable to the caffeine
amount in 2 cups of coffee, caused a significant attenua-
tion of EEG power in various brain regions. It has been
shown that cerebral metabolism and EEG power are
inversely related in normal subjects [29]. Caffeine acts as
a vasoconstrictor. It subsequently decreases cerebral volt-
age. Usage of caffeine may affect cerebral functioning
more profoundly than has previously been suspected.
While quantitative EEG is being increasingly used to
study neurophysiologic effects of various substances, caf-
feine usage is not currently considered or controlled in
such investigations. Our findings suggest that usage of rel-
atively small amounts of caffeine may have a significant
effect on cerebral voltage. Of particular importance would
be studying chronic caffeine use and evaluation of fre-
quency changes.
In conclusion, single doses of 200 mg of caffeine atten-
uate EEG power at various electrode positions. The effect
is most pronounced in the alpha bands.
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